Case Report Describes First Known Ocular Myasthenia Gravis Case with COVID-19
source: pixabay.com

Case Report Describes First Known Ocular Myasthenia Gravis Case with COVID-19

According to a story from Myasthenia Gravis News, a recent report describes the first-ever documented case of a patient developing the ocular variant of myasthenia gravis in connection with COVID-19…

Continue Reading Case Report Describes First Known Ocular Myasthenia Gravis Case with COVID-19
Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
source: pixabay.com

Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis

  According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…

Continue Reading Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients
source: pixabay.com

New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients

  New information, speculation, statistics, and predictions about COVID-19 are hitting the internet every day. Yet neurologists are attempting to answer their patients’ questions without having sufficient data that would…

Continue Reading New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients

Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes

Firdapse, or amifampridine phosphate, is a medication currently approved for Lambert-Eaton myasthenic syndrome, or LEMS. However, Catalyst Pharmaceuticals has been working to evaluate if it can aid other neurological and…

Continue Reading Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes